ARGX vs. JAZZ: argenx vs. Jazz Pharmaceuticals Stock Comparison

Company Profile

argenx (ARGX) and Jazz Pharmaceuticals (JAZZ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ARGX is classified in Biotechnology while JAZZ is classified in Pharmaceuticals.

Jazz Pharmaceuticals (JAZZ) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Jazz Pharmaceuticals (JAZZ) earns 5.05% on shareholders’ equity, ranked against its industry; argenx (ARGX) has no ROE this period.

argenx (ARGX) at 31.73% converts revenue to bottom-line profit above its industry’s benchmark range, while Jazz Pharmaceuticals (JAZZ) at 4.37% keeps roughly the typical share for its industry.

Both argenx (ARGX) at 36.27% and Jazz Pharmaceuticals (JAZZ) at 30.17% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Jazz Pharmaceuticals (JAZZ) at 4.88% is closer to the peer norm — faster top-line expansion for ARGX.

argenx (ARGX) at 53.13% is around its peer norm for EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% drops into the bottom quartile, signaling weaker earnings momentum.

Growth Metrics

Financial Strength

Short-term liquidity can only be read on one side of this pairing: Jazz Pharmaceuticals (JAZZ) shows current ratio of 1.82 against its industry benchmark, while argenx (ARGX) has no reading this period.

argenx (ARGX) at 0.01 keeps leverage in the lower quartile, while Jazz Pharmaceuticals (JAZZ) at 1.35 sits in the higher-leverage quartile.

Financial Strength Metrics

Dividends

Neither argenx (ARGX) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither argenx (ARGX) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

argenx (ARGX) at 32.12 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both argenx (ARGX) at 9.86 and Jazz Pharmaceuticals (JAZZ) at 3.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Jazz Pharmaceuticals (JAZZ) at 3.59 sits near its industry’s typical P/B ratio, while argenx (ARGX) at 172.23 prices above its benchmark range — ARGX looks rich relative to book.

Valuation Metrics